Is Ketamine Neurotoxic?

Original Article ↗ Hacker News Discussion ↗

Claims that ketamine is highly neurotoxic prompt scrutiny of dosage, route of administration, and what counts as “average use,” with many pointing out that the article in question conflates therapeutic IV doses with much larger recreational intranasal amounts. Commenters note that ketamine, an NMDA receptor antagonist, can both promote neuroplasticity and carry significant neurotoxic risk at high or prolonged doses, paralleling the “dose makes the poison” trade‑off seen with many psychoactive drugs. The thread broadens into concerns about long‑term brain effects, tolerance, and trust in psychiatric treatments—from ketamine infusions and ECT to stimulants for ADHD—underscoring the need for careful medical supervision and better-quality evidence.

Dosage, Routes, and Article Accuracy

  • Multiple commenters attack the article’s dose comparison as wrong or misleading:
    • 0.5 mg/kg is a per-dose IV/IM amount (often given 1–2×/week for depression, more for anesthesia), not a daily oral/intranasal amount.
    • 0.5 mg/kg for a 70 kg person is ~35 mg IV; saying 500–1000 mg/day is “100–300×” this is mathematically off, and also ignores route-of-administration (ROA).
  • ROA matters: rough figures cited are ~100% bioavailability IV, ~80% IM, ~20% intranasal, so mg numbers are not directly comparable.
  • Several people say 1 g/day is an extreme but real dose among chronic abusers; others note typical recreational doses are in the 30–75 mg/snorted range.
  • There’s confusion over what “average user” means. Many argue the article is really describing heavy/chronic abusers, not typical experimenters or occasional users.
  • Commenters also note other basic pharmacology errors and uncited claims, leading some to dismiss the article as sloppy or conclusion-driven.

Neurotoxicity vs. Neuroplasticity

  • One side stresses: ketamine (an NMDA receptor antagonist) and other NMDA-modulating drugs have well-known neurotoxic potential, especially at high or prolonged doses (e.g., lesions in animal models).
  • The other side highlights evidence that single or limited therapeutic doses increase neuroplasticity (BDNF, mTOR, synaptogenesis) in depression-relevant brain regions.
  • A key reconciliation suggested: both can be true. The same mechanism can yield beneficial plasticity at carefully controlled doses and regimens, and harmful structural changes with heavy, chronic, or high-dose exposure.
  • Some mention dopaminergic effects and strong tolerance, including reports that heavy users need gram-level doses and that tolerance may reappear quickly after abstinence.

Recreational vs. Therapeutic Risk

  • Broad agreement that:
    • Physician-supervised ketamine (e.g., IV infusions or monitored intranasal/lozenges) can be very effective for treatment-resistant depression/PTSD.
    • Street ketamine poses additional risks (adulterants, uncontrolled dosing).
  • Debate on severity and prevalence of harm:
    • Some report seeing dramatic cognitive decline and psychosis in heavy users.
    • Others emphasize few deaths from ketamine alone relative to opioids, but still warn about cardiovascular strain and bladder damage with long-term high-dose use.
    • Occasional deep “K-hole” use is described anecdotally, but its long-term risk level is seen as unclear.

Tolerance, Other Psych Meds, and Trust in Doctors

  • Ketamine tolerance is described as unusually persistent compared to stimulants, where breaks can reset sensitivity.
  • A long subthread compares this to Adderall/methylphenidate:
    • Some advise trusting psychiatrists’ dosing recommendations.
    • Others stress patient self-education and advocacy, citing overprescribing, side-effects, and the opioid crisis as reasons for skepticism.

Extreme Outcomes and Other Interventions

  • A widely discussed suicide note from a researcher who used ketamine and underwent ECT prompts:
    • Strong emotional reactions and reflection on depression, ambition, and meaning.
    • Disagreement about ECT: some say it can be life-saving; others report severe memory loss and no benefit.
  • Several commenters close with a pragmatic stance: high-powered interventions (ketamine, ECT) can be worth trying in severe, suicidal depression, but should be approached cautiously, with awareness of uncertain long-term neurotoxicity at higher or chronic doses.